Biotech News
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
ir.kalvista.com2026-05-06 15:26 EST
New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation FRAMINGHAM, Mass. & SALISBURY, England--( BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one